MAP3K3 and cerebrocostomandibular syndrome: Even with the tremendous advancements in next generation sequencing and common use of high coverage targeted sequencing including genes known to cause CCMs, two critical facts remain true— (1) the majority of CCM lesions with reported DNA sequence analysis lack either an activating variant in an oncogene or either biallelic loss-of-function variants in a CCM gene or an activating variant in MAP3K3 and (2) surgical resection remains the only available therapy for CCMs.